Sodium‐glucose co-transporter 2 (SGLT2) inhibitors have recently emerged as an effective means to protect kidney function in people with type 2 diabetes and chronic kidney disease (CKD). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.